Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to give written consent before any trial procedures begin
• People aged 18 to 75, of any gender
• People whose general physical functioning is rated at a level showing they are able to carry out at least some daily activities (a standard performance scale score of 0–2, confirm with trial site)
• People who have been diagnosed through lab testing with head and neck squamous cell carcinoma (a type of cancer) that has come back or spread, specifically involving the oropharynx, mouth, hypopharynx, or voice box
• People who have already received at least one systemic (whole-body) treatment for their returned or spread head and neck cancer
• People whose life expectancy is greater than 3 months
• People who have at least one tumour that can be measured using standard imaging criteria
• People whose side effects from any previous cancer treatment have largely or fully resolved before joining
• People whose thyroid hormone levels (T3 and T4) are within the normal range, or are being managed with thyroid medication, or who have abnormal levels but no symptoms (confirm with trial site)
• People whose blood counts, liver function, kidney function, and blood clotting results meet specific minimum standards on testing done within 7 days before joining (confirm exact values with trial site)

Who may not be able to join:

• People with a confirmed history of a different type of cancer unrelated to head and neck squamous cell carcinoma
• People whose cancer has spread to the brain or central nervous system
• People with active hepatitis B or C infections, or certain hepatitis virus levels that have not responded to antiviral treatment, or who test positive for both hepatitis B and hepatitis C markers at the same time
• People who have had a serious, life-threatening bleeding episode in the past 3 months, including one that needed a blood transfusion, surgery, or ongoing treatment
• People who have had a blood clot-related event in the past 6 months, such as a heart attack, stroke, pulmonary embolism, or deep vein thrombosis (confirm with trial site for exceptions)
• People who have taken high-dose aspirin (more than 325 mg per day) or certain other blood-thinning medications for 10 or more consecutive days in the 2 weeks before the first dose
• People with significant heart failure symptoms, poorly controlled irregular heartbeat, a history of a specific heart rhythm disorder called long QT syndrome, or a particular heart measurement that is too high on screening
• People with a serious tendency to bleed, a clotting disorder, or who are currently receiving clot-dissolving therapy
• People with a history of a hole or abnormal opening in the gut, bowel blockage, major bowel removal, Crohn's disease, ulcerative colitis, or long-term chronic diarrhoea, within the past 6 months
• People with a current or past history of serious lung conditions such as pulmonary fibrosis, interstitial pneumonia, or severely reduced lung function
• People with a known history of alcohol abuse, misuse of mind-altering substances, or illicit drug use
• People with a history of certain neurological or psychiatric conditions such as epilepsy, dementia, or schizophrenia
• People with active tuberculosis, who are currently receiving tuberculosis treatment, or who received tuberculosis treatment within one year before the first dose
• People who are HIV-positive or who have a known syphilis infection
• People with active severe infections, or who were hospitalised for a serious infection within 4 weeks before the first dose
• People who have had an active autoimmune disease requiring systemic treatment within the past 2 years (some replacement therapies are permitted — confirm with trial site)
• People who have used immune-suppressing medications within 4 weeks before the first dose (some low-dose or topical exceptions may apply — confirm with trial site)
• People who have received a live vaccine within 4 weeks before the first dose, or who are scheduled to receive one during the study
• People who have had major surgery such as brain, chest, or abdominal surgery within 4 weeks before the first dose, or who have wounds, ulcers, or fractures that have not healed
• People with uncontrolled metabolic disorders or other serious non-cancer organ or body system conditions
• People who have been diagnosed with another cancer within the past 5 years (some fully treated skin cancers may be excepted — confirm with trial site)
• People with a history of severe allergic reactions to any of the study drug components, including certain antibody treatments, platinum-based drugs, docetaxel, or paclitaxel
• People who have taken part in another clinical trial or are currently in another clinical study within 4 weeks before the first dose
• People who are pregnant or breastfeeding
• People with other medical, psychiatric, or laboratory findings that, in the treating doctor's judgement, would make participation unsafe or affect the reliability of study results

Important: Always verify eligibility with the trial site directly before applying.